Which protein serves as the common target for CAR T-cell therapy in B-cell cancers?
Answer
The CD19 protein
In many FDA-approved CAR T-cell therapies, the target antigen is the CD19 protein. This protein is prominently displayed on the surface of most B-cell cancers, including various aggressive lymphomas and leukemias. By equipping T-cells with a receptor designed to lock onto CD19, the engineered cells can effectively locate and destroy B-cells expressing this marker, providing a targeted approach to eradicating cancer cells regardless of whether they are in the bone marrow or elsewhere in the body.
Related Questions
What is the defining characteristic of CAR T-cell therapy?Which protein serves as the common target for CAR T-cell therapy in B-cell cancers?What is the primary function of the leukapheresis procedure?What role does a vector derived from a deactivated virus play in T-cell engineering?How does TCR cell therapy differ from CAR T-cell therapy regarding antigen recognition?What triggers the onset of Cytokine Release Syndrome or CRS?What distinguishes neurotoxicity or ICANS from other CAR T-cell therapy side effects?What is the purpose of bridging chemotherapy during the waiting period?What defines the expansion phase in the CAR T-cell manufacturing protocol?What is the intended advantage of developing off-the-shelf allogeneic products?